ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0342

Evaluation of Urinary NHE3 in Rats with AKI

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Xie, Anni, The Core Laboratory,Nanjing BenQ Medical Center,The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
  • Ren, Zhiyun, The Core Laboratory,Nanjing BenQ Medical Center,The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
  • Liu, Mingda, The Core Laboratory,Nanjing BenQ Medical Center,The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
  • Yu, Yanting, The Core Laboratory,Nanjing BenQ Medical Center,The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
  • Wang, Xiaoyan, The Core Laboratory,Nanjing BenQ Medical Center,The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Group or Team Name

  • The Core Laboratory for Clinical Research
Background

Acute kidney injuries (AKIs), caused by hypovolemia, ischemia-reperfusion, or nephrotoxins , are concerned with high morbidity and mortality. Urinary Na/H exchanger isoform 3 (NHE3) has been demonstrated as a noninvasive marker of acute tubular necrosis. However, the ideal diagnostic biomarker in AKI is still lacking.

Methods

In order to determine the potential role of urinary NHE3 in early diagnosis of AKI,we evaluated the exosome NHE3 in daily urines from rat models of AKIs including low NaCl (0.01%) plus candesartan (1mg/kg/day, IP) for 7 days, ischemia/reperfusion (ischemia for 40min,referfusion for 2h)and cisplatin(20mg/kg for 7 days) in Sprague Dawley rats (male, 2-3 months old, 4-7 rats per group). Urine exosomes were isolated by a series of centrifuges including ultracentrifuges (17k xg,4°C,10min;200k xg,4°C,1 hr).

Results

NHE3 levels (western blotting) were increased at day 1, which was 1 day before serum creatinine increased in low NaCl/candesartan rats and reperfusion rats (day1) relative to controls. They were also increased in cisplatin rats at day 2 (1 day before serum creatinine increased). Furthermore, NHE3 in original urines from 6 patients diagnosed with AKI ( Scr 249.83 ±166.93 umol/L) and 6 volunteers with normal renal function (Scr 68.67±13.20umol/L) were assessed without ultracentrifuge isolation. NHE3 was increased remarkably in AKI patients (333±28, % of controls) compared with volunteers (100±30, %, t-test, P<0.05).

Conclusion

Our results in rats and patients suggest that assessment of urine NHE3 may be a potential non-invasive biomarker for early detection of various acute kidney injuries.

Funding

  • Government Support – Non-U.S.